Discovery of N,4-Di(1H-pyrazol-4-yl)pyrimidin-2-amine-Derived CDK2 Inhibitors as Potential Anticancer Agents: Design, Synthesis, and Evaluation
Molecules · 25.03.2023 · 28 (7) · 2951
DOI: 10.3390/molecules28072951 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecules, online erschienen am 25.03.2023. Verfasst von Biruk Sintayehu Fanta und 10 weiteren Autor:innen. Beteiligte Einrichtung: Drug Discovery and Development, Clinical and Health Sciences, University of South Australia, Adelaide, SA 5000, Australia. Hauptthemen laut MEDLINE: Antineoplastic Agents, Neoplasms. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Cyclin-dependent kinase 2 (CDK2) has been garnering considerable interest as a target to develop new cancer treatments and to ameliorate resistance to CDK4/6 inhibitors. However, a selective CDK2 inhibitor has yet to be clinically approved. With the desire to discover novel, potent, and selective CDK2 inhibitors, the phenylsulfonamide moiety of our previous lead compound 1 was bioisosterically replaced with pyrazole derivatives, affording a novel series of N,4-di(1H-pyrazol-4-yl)pyrimidin-2-amines that exhibited potent CDK2 inhibitory activity. Among them, 15 was the most potent CDK2 inhibitor (Ki = 0.005 µM) with a degree of selectivity over other CDKs tested. Meanwhile, this compound displayed sub-micromolar antiproliferative activity against a panel of 13 cancer cell lines (GI50 = 0.127–0.560 μM). Mechanistic studies in ovarian cancer cells revealed that 15 reduced the phosphorylation of retinoblastoma at Thr821, arrested cells at the S and G2/M phases, and induced apoptosis. These results accentuate the potential of the N,4-di(1H-pyrazol-4-yl)pyrimidin-2-amine scaffold to be developed into potent and selective CDK2 inhibitors for the treatment of cancer.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Drug Discovery and Development, Clinical and Health Sciences, University of South Australia, Adelaide, SA 5000, Australia.
ORCID-Profile: Biruk Sintayehu Fanta, Laychiluh Mekonnen, Yuchao Yang, Matthew J Sykes, Mingfeng Yu, Shudong Wang
Zitieren
APA
Fanta, B. S., Lenjisa, J., Teo, T., Kou, L., Mekonnen, L., Yang, Y., Basnet, S. K. C., Hassankhani, R., Sykes, M. J., Yu, M., & Wang, S. (2023). Discovery of N,4-Di(1H-pyrazol-4-yl)pyrimidin-2-amine-Derived CDK2 Inhibitors as Potential Anticancer Agents: Design, Synthesis, and Evaluation. Molecules, 28(7), 2951. https://doi.org/10.3390/molecules28072951
Vancouver
Fanta BS, Lenjisa J, Teo T, Kou L, Mekonnen L, Yang Y, et al. Discovery of N,4-Di(1H-pyrazol-4-yl)pyrimidin-2-amine-Derived CDK2 Inhibitors as Potential Anticancer Agents: Design, Synthesis, and Evaluation. Molecules. 2023;28(7):2951. doi:10.3390/molecules28072951
BibTeX
@article{Fanta2023,
author = {Fanta, Biruk Sintayehu and Lenjisa, Jimma and Teo, Theodosia and Kou, Lianmeng and Mekonnen, Laychiluh and Yang, Yuchao and Basnet, Sunita K C and Hassankhani, Ramin and Sykes, Matthew J and Yu, Mingfeng and Wang, Shudong},
title = {Discovery of N,4-Di(1H-pyrazol-4-yl)pyrimidin-2-amine-Derived CDK2 Inhibitors as Potential Anticancer Agents: Design, Synthesis, and Evaluation},
journal = {Molecules},
year = {2023},
volume = {28},
number = {7},
pages = {2951},
doi = {10.3390/molecules28072951}
}
EUVIMED